Science and Research

Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort

BACKGROUND: Severe asthma affects less than 5% of asthmatics, but is associated with high costs and increased mortality. The aim of this study was to assess age- and sex-dependent differences in this patient group. METHODS: Retrospective analysis of 1317 children and adults with severe asthma who are included in the German Asthma Net registry. RESULTS: There were more adults than children in the registry and patients' mean age was 52. Apart from children <18 years, there were more women (57%) than men. The age of first diagnosis ranged from 0 to 76 years. 38% of patients had a positive bronchial reversibility after short acting bronchodilators. Quality of life, FEV1 and MEF 25 decreased with older age whereas treatment with oral steroids and monoclonal antibodies increased. An anti-eosinophil treatment was most frequently used in patients aged around 57 years, while an anti-IgE treatment was used in all age-groups including children. There were sex-dependent differences with lower values in men for FEV1, FVC, MEF 25 and DLCO. Yet, women were more frequently unable to work than men due to the disease. CONCLUSION: In patients with severe asthma, clinical characteristics, but also treatments differed between age groups and between the sexes, reflecting different phenotypes of the disease.
  • Milger, K.
  • Korn, S.
  • Buhl, R.
  • Hamelmann, E.
  • Herth, F. J.
  • Gappa, M.
  • Drick, N.
  • Fuge, J.
  • Suhling, H.

Keywords

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Asthmatic Agents/therapeutic use
  • Antibodies, Monoclonal/therapeutic use
  • Asthma/*drug therapy/epidemiology/physiopathology/therapy
  • Bronchodilator Agents/*therapeutic use
  • Child
  • Child, Preschool
  • Cohort Studies
  • Female
  • Germany/epidemiology
  • Glucocorticoids/therapeutic use
  • Humans
  • Immunoglobulin E/immunology
  • Infant
  • Male
  • Maximal Expiratory Flow Rate
  • Middle Aged
  • Omalizumab/therapeutic use
  • Quality of Life
  • Retrospective Studies
  • Severity of Illness Index
  • Sex Factors
  • Young Adult
  • *Age
  • *Antibody therapy
  • *Lung function
  • *Severe asthma
  • *Sex
  • competing financial interests or personal relationships that could have appeared
  • to influence the work reported in this paper.
Publication details
DOI: 10.1016/j.rmed.2019.105858
Journal: Respir Med
Pages: 105858 
Work Type: Original
Location: BREATH, CPC-M, TLRC
Disease Area: AA
Partner / Member: LMU, MHH, Thorax
Access-Number: 31916535
See publication on PubMed

DZL Engagements

chevron-down